Alzheimer's disease is a major cause of
dementia in humans. The appearance of
cognitive decline is linked to the overproduction of a short
peptide called
beta-amyloid (Abeta) in both soluble and aggregate forms. Here, we show that injecting
macrophage colony-stimulating factor (
M-CSF) to Swedish
beta-amyloid precursor
protein (APP(Swe))/PS1 transgenic mice, a well-documented model for
Alzheimer's disease, on a weekly basis prior to the appearance of learning and
memory deficits prevented cognitive loss.
M-CSF also increased the number of microglia in the parenchyma and decreased the number of Abeta deposits.
Senile plaques were smaller and less dense in the brain of
M-CSF-treated mice compared to littermate controls treated with vehicle
solution. Interestingly, a higher ratio of microglia internalized Abeta in the brain of
M-CSF-treated animals and the phagocytosed
peptides were located in the late endosomes and lysosomes. Less Abeta(40) and Abeta(42) monomers were also detected in the extracellular
protein enriched fractions of
M-CSF-treated transgenic mice when compared with vehicle controls. Finally, treating APP(Swe)/PS1 mice that were already demonstrating installed Abeta pathology stabilized the
cognitive decline. Together these results provide compelling evidence that systemic
M-CSF administration is a powerful treatment to stimulate bone marrow-derived microglia, degrade Abeta and prevent or improve the
cognitive decline associated with Abeta burden in a mouse model of
Alzheimer's disease.